February 2021, Drugs Monitor

(17 Feb 2021) Anakinra-not useful to improve the prognosis of patients with tocilizumab-refractory severe COVID-19

February 19, 2021

Effectiveness of anakinra for tocilizumab-refractory severe COVID-19. A single centre retrospective comparative study https://doi.org/10.1016/j.ijid.2021.02.041 A prospective cohort of patients with COVID19 pneumonia who received anakinra as salvage therapy after failure of tocilizumab were compared (1:1) to selected controls in a… Continue reading "(17 Feb 2021) Anakinra-not useful to improve the prognosis of patients with tocilizumab-refractory severe COVID-19"

(17 Feb 2021) Tocilizumab- reduction in ICU stay and ventilatory care need

February 19, 2021

Safety and Efficacy of Tocilizumab in the Treatment of Severe Acute Respiratory Syndrome Coronavirus-2 Pneumonia: A Retrospective Cohort Study https://doi.org/10.4103/ijmm.IJMM_20_298 A total of 20 patients received TCZ during the study period. The median age was 54 years (95% confidence interval… Continue reading "(17 Feb 2021) Tocilizumab- reduction in ICU stay and ventilatory care need"

(17 Feb 2021) Ivermectin- associated with a 73% reduction of SARS-CoV-2 infection among healthcare workers

February 19, 2021

Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study https://doi.org/10.1371/journal.pone.0247163 Ivermectin prophylaxis was taken by 76 controls and 41 cases. Two-dose ivermectin prophylaxis (AOR 0.27, 95% CI, 0.15-0.51) was associated with… Continue reading "(17 Feb 2021) Ivermectin- associated with a 73% reduction of SARS-CoV-2 infection among healthcare workers"

(17 Feb 2021) Nitazoxanide, Ivermectin, Ribavirin- plus Zinc effectively clear the SARS-COV2 from nasopharynx

February 19, 2021

Effect of a combination of Nitazoxanide, Ribavirin and Ivermectin plus zinc supplement (MANS.NRIZ study) on the clearance of mild COVID-19 https://doi.org/10.1002/jmv.26880 NCT04392427- This non-randomized controlled trial included 62 patients on triple combination treatment versus 51 age- and sex-matched patients on… Continue reading "(17 Feb 2021) Nitazoxanide, Ivermectin, Ribavirin- plus Zinc effectively clear the SARS-COV2 from nasopharynx"

(13 Feb 2021) TNR4 therapy- 75% and 81% lower risk of being hospitalized or death

February 16, 2021

Effectiveness of a multidrug therapy consisting of ivermectin, azithromycin, montelukast and acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico https://doi.org/10.1016/j.ijid.2021.02.014 The aim of this study was to assess the effectiveness of a multidrug-therapy consisting… Continue reading "(13 Feb 2021) TNR4 therapy- 75% and 81% lower risk of being hospitalized or death"

(11 Feb 2021) Tocilizumab- improved survival and other clinical outcomes

February 16, 2021

Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial https://www.medrxiv.org/content/10.1101/2021.02.11.21249258v1 NCT04381936 RECOVERY Trial-Between 23 April 2020 and 24 January 2021, 4116 adults were included in the assessment of tocilizumab, including 562… Continue reading "(11 Feb 2021) Tocilizumab- improved survival and other clinical outcomes"

(11 Feb 2021) Corticosteroids- overall all-cause mortality was significantly lower

February 16, 2021

Safety and Efficacy of Low-Dose Corticosteroids in Patients With Non-severe Coronavirus Disease 2019: A Retrospective Cohort Study https://doi.org/10.7759/cureus.12544 A retrospective cohort study involving 25 patients with a confirmed diagnosis of non-severe COVID-19 infection was conducted. Subjects were assigned to either… Continue reading "(11 Feb 2021) Corticosteroids- overall all-cause mortality was significantly lower"

(09 Feb 2021) Interferon lambda- potential to prevent clinical deterioration and shorten duration of viral shedding

February 16, 2021

Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial https://doi.org/10.1016/S2213-2600(20)30566-X NCT04354259-The decline in SARS-CoV-2 RNA was greater in those treated with peginterferon lambda than placebo from day 3 onwards, with a difference of 2.42… Continue reading "(09 Feb 2021) Interferon lambda- potential to prevent clinical deterioration and shorten duration of viral shedding"

(09 Feb 2021) Anakinra- did not show a significant advantage over SOC alone

February 16, 2021

Efficacy of early anti-inflammatory treatment with high doses IV Anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia https://doi.org/10.1016/j.jaci.2021.01.024 128 patients were analyzed; 63 received early AIT (30 anakinra, 33 anakinra and CG) at admission; 65 patients (44… Continue reading "(09 Feb 2021) Anakinra- did not show a significant advantage over SOC alone"

(08 Feb 2021) Budesonide- inhaled budesonide reduced time to recovery

February 16, 2021

Inhaled budesonide in the treatment of early COVID-19 illness: a randomised controlled trial https://www.medrxiv.org/content/10.1101/2021.02.04.21251134v1 NCT04416399- 146 patients underwent randomisation. For the per protocol population (n=139), the primary outcome occurred in 10 participants and 1 participant in the usual care… Continue reading "(08 Feb 2021) Budesonide- inhaled budesonide reduced time to recovery"

Month: February 2021